To assess whether or not liver transplantation and subsequent immunosuppression with
found in association with inflammatory bowel disease, particularly ulcerative colitis (1) (2) (3) (4) (5) (6) (7) (8) . Liver transplantation has been used to treat individuals with advanced primary sclerosing cholangitis only recently (9) (10) (11) (12) (13) .
Whether or not primary sclerosing cholangitis recurs following liver transplantation and what the effect of the persistent presence of inflammatory bowel disease might have upon the clinical course and quality of life of patients receiving a liver transplant for advanced primary sclerosing cholan-gitis are unknown. Immunological factors are thought to be important in the pathogenesis of both sclerosing cholangitis and the underlying inflammatory bowel disease (14) (15) (16) (17) (18) (19) . The present study was performed in a case series to evaluate ulcerative colitis symptomatology as assessed by patientcompleted questionnaires following liver transplantation for end-stage liver disease.
MATERIALS AND METHODS
Between June 1982 and September 1985, a total of 35 patients with colonoscopy-and biopsy-documented ulcerative colitis underwent orthotopic liver transplantation (OLTx) at the University of Pittsburgh. The indication for OLTx was primary sclerosing cholangitis in 34 and congenital hepatic fibrosis in one. All patients were evaluated as potential liver recipients using the liver transplant protocol, which includes a full colonoscopy, in use at the institution. All the patients had an intact colon at time of transplant. Of these 35 patients, 12 died within 139 + 55 days (mean -+ SEM) of surgery.
The surviving 23 patients were sent a detailed questionnaire to assess their perception of their ability to function in usual activities, the status and severity of ulcerative colitis symptoms, medication usage, and occurrence of and treatment for ulcerative colitis flares (see Appendix). The response rate was 100%; in addition, follow-up phone calls were made to clarify ambiguous responses and to obtain missing information. Subjects were asked to classify the ulcerative colitis symptoms and severity, during the year prior to transplant and during the three month period prior to the time at which the questionnaire was completed, by indicating which of several categories provided best described a given symptom.
The data were analyzed using the McNemar test of symmetry to evaluate changes in the proportion of patients in ulcerative colitis symptom severity categories, comparing the year prior to OLTx and the follow-up time point, which was at a different postoperative time point for each patient. Because of the relatively small number of patients who had had symptomatic ulcerative colitis prior to transplantation (N = 17), frequency categories for crampy abdominal pain, rectal pain, bowel urgency, rectal bleeding, and the presence of pus or mucus in the stool were combined as follows: frequency of symptoms more than or equal to several times a week was classified as high frequency, while the occurrence of symptoms several times a month or less was classified as low frequency. The binomial test was used to examine proportions of patients who either improved or did not improve with respect to symptoms or functional status. Continuous data are reported as the mean -+ SEM. Differences at the P < 0.05 level were considered to be statistically significant.
RESULTS

Quiescent
Group. Six (26%) of the 23 patients had quiescent ulcerative colitis prior to liver transplan-GAVALER ET AL tation and had not required treatment for their ulcerative colitis. Colonoscopy with multiple colonic biopsies documented pancolitis to be present in all. The indication for OLTx in these six patients was primary sclerosing cholangitis. This clinically quiescent ulcerative colitis subgroup of four males and two females was 34.7 + 6.2 years of age at time of OLTx, and the duration of their follow-up post OLTx was 109.9 -+ 5.9 weeks (range: 104-136 weeks). The daily immunosuppressive regimen in this group was 400.0 -+ 44.7 mg of cyclosporine and 10.8 -+ 0.5 mg of prednisone. At time of follow-up, five patients (83.3%) were working full-time and one was not working but able to care for herself at home. All six patients reported themselves to be free of ulcerative colitis symptoms following transplantation.
Symptomatic Group. Seventeen patients, 11 males and six females, had had symptomatic ulcerative colitis prior to transplantation. Seven of these patients (40%) had mild clinical ulcerative colitis, eight had moderate colitis (47%), and two (13%) had severe clinical colitis. The duration of ulcerative colitis prior to OLTx was 15.4 + 1.9 years. (The initial onset had been mild in 29.4%, moderate in 47.1%, and severe in 23.5%). The course of the ulcerative colitis had been continuous in 35.3% and intermittent in 64.7%. Among the 11 patients with an intermittent course, the intervening attacks had been severe in two, moderate in seven, and mild in two. Prior to transplant, 66.7% of these patients had been treated for their ulcerative colitis with sulfasalazine, 46.7% with steroid enemas, 40.0% with Lomotil, 26.7% with prednisone, and 18.8% with azathioprine. Colonoscopy performed during evaluation for liver transplantation demonstrated pancolitis to be present in all 17 patients. Histologically, prior to transplantation, 80% of the subjects had minimal disease based upon a histologic examination of multiple colonic biopsies obtained at the time of the preoperative colonoscopy. Ten percent of the subjects had moderate and 10% had severe colitis histologically.
At time of transplant, the mean range was 39.8 -+ 1.6 years; the indication for OLTx was primary sclerosing cholangitis in 16 and congenital hepatic fibrosis in one. In this subgroup of 17 patients with symptomatic ulcerative colitis prior to OLTx, the duration of follow-up was 82.7 -+ 9.6 weeks. (range: 31-175 weeks). At time of follow-up, the daily immunosuppressive regimen was 383.8 -+ 27.2 mg of cyclosporine and 13.8 -+ 0.8 mg of prednisone; in addition, 23.5% were taking sulfasalazine, and 5.9% were using diphenoxylate hydrochloride with atropine sulfate (Lomotil).
In the symptomatic group, in response to the question, "overall, since your liver transplant, are the symptoms of your ulcerative colitis better, worse or the same?", 82.4% indicated improvement, none reported a worsening, and 17.6% indicated no change (P < 0.001 compared to preOLTx). Of the three patients reporting no change, however, two reported that the overall severity of colitis symptoms continued to be moderate following OLTx and one reported a shift from severe to moderate overall colitis severity.
A separate question was asked about overall symptom severity. During the year prior to transplant, the overall severity of colitis symptoms was rated as having been severe by 35.3%, moderate by 52.9%, and mild by 11.8% of these patients. In contrast, at follow-up, 88.2% patients reported improvement, with 52.9% reporting no colitis symptoms, 29.4% mild symptoms, 17.6% moderate symptoms, and none indicating severe colitis symptoms (P < 0.001, pre-versus post-OLTx, mild versus moderate plus severe symptom categories combined).
The frequencies of various ulcerative colitis symptoms before and after transplantation are shown in Table 1 . The percentages of patients who indicated improvement in symptom severity or frequency were calculated and tested using the binomial test; the results are summarized in Table  2 . In assessing improvement, all stated levels of severity or frequency were used, and a shift from a more severe to a less severe category was considered to be improvement. Further, those patients reporting no abnormality prior to OLTx (eg, 1 to 2) bowel movements per day or a frequency of "never") were not considered to be "at risk" for improvement and thus were not included in the denominator for these calculations. As may be seen in Table 2 , compared to the year prior to OLTx, there was significant improvement at time of follow-up in overall colitis symptom severity, and the frequency of occurrence of daily bowel movements, crampy abdominal pain, bowel urgency, the presence of pus or mucus in the stool, and the occurrence of flares. There was no significant improvement in either rectal pain or rectal bleeding. Among the eight patients experiencing a flare, the mean interval between OLTx and the first flare was 37.0 +-9.1 weeks; the earliest flare *Test of differences in proportions before and after transplantation. ?a = 1-2 bowel movements per day; b = three or more bowel movements per day; c = occurrence several days a month or less; d = occurrence several times a week or more.
reported occurred at 12 weeks, while one patient indicated the first flare to have occurred as late as 85 weeks. Nine patients reported that colonoscopy (N = 7) or barium enema (N = 2) had been performed during the follow-up period (No patient reported the occurrence of colon surgery following transplantation.) The histological appearance in 16 of the 17 patients with symptomatic colitis Two aspects of quality of life were assessed: the first involved the impact of ulcerative colitis symptoms on the ability to function normally in daily activities, and the second assessed the overall impact of liver transplantation with immunosuppression as estimated by changes in the ability to work or carry out normal activities. As may be seen in Table 3 , the impact of ulcerative colitis symptomatology on the ability to function normally was substantially less, but not eliminated, during the follow-up period. Of the 17 with syrup: tomatic disease, 11 patients reported improvement and six reported no change; of these six, three reported that there had been no days during which their ulcerative colitis symptoms had prevented them from functioning normally during the year prior to transplant. Thus, there was overall improvement in 11 of the 14 patients (78.6%) who had been unable to function normally at least once a month pretransplant (P < 0.006). None of these patients had been able to function normally, as measured by the ability to work or participate in usual activities, at time of transplantation because of the severity of their liver disease. Thus, the responses to the question "which category best describes your present activity?" primarily reflect the effect of transplantation, which reversed the end-stage liver disease. As may be seen in Table 4 , altogether 13 of the 17 patients reported an improvement in their overall ability to pursue normal activities following liver transplantation (P < 0.006). This finding suggests that ability to work or feeling well enough to work following transplantation may have reflected factors other than ulcerative colitis disease activity per se.
DISCUSSION
The results of this study using a survey questionnaire suggest that ulcerative colitis disease activity as subjectively characterized by each patient significantly improves in the short run (31-175 weeks) following liver transplantation for end-stage liver disease. This improvement following transplantation could be ascribed to the transplant, the use of cyclosporine and prednisone, the changes in lifestyle or emotional support, or the mandatory period of rest. With respect to the possible role of immunosuppression, it is to be noted that short-term cyclosporine administration to small groups (N = 1-6 patients) with ulcerative colitis or Crohn's disease has been reported to improve symptoms in the majority of such patients (20) (21) (22) . Similarly, corticosteroids also have been used successfully to treat ulcerative colitis. Thus it should be noted that in the current study, the steroid portion of the immunosuppression regimen was 10.8 -+ 0.5 rag/day of prednisone among the six asymptomatic patients and 13.8 -+ 0.8 rag/day among the 17 patients who had been symptomatic prior to transplantation. In addition, psychological factors also may play a role in perceived improvement. The reversal of endstage liver disease, resulting in a lessened inward focus on status of physical being and an increased interest in or more hopeful attitude toward outward activities that have come within reach as a result of the liver disease having been "cured," may be a reason for the observed improvement (23) (24) (25) .
The findings of this study also raise questions about the perception of ulcerative colitis symptoms and their severity. Specifically, prior to transplantation, the study group could be divided into two groups: those with and those without ulcerative colitis symptoms. The first unanswered question arises from the fact that both of these groups were comprised of individuals with comparable colonoscopy-documented pancolitis. The second unanswered question arises from the information provided by the 17 patients who had had symptomatically active ulcerative colitis prior to transplant: Why is it that during the follow-up period, 17.6% of these patients reported no change in response to the question "are the symptoms of your ulcerative colitis better, worse, or the same," when at the same time they indicated the overall severity of their colitis to have decreased at the time of follow-up? Such discrepancies emphasize the problem of deciphering the interrelationships of perceived improvement, recall of symptomatology, and relative changes either in actual disease activity or symptom severity. Specific answers to the questions and issues raised are beyond the scope of the current study. Future studies, which may include such objective measures as colonoscopy findings or adsorption/absorption assessment of topical versus humoral delivery of cyclosporine or new immunosuppressive drugs such as FK506, may provide useful information. Neuropsychological assessments might also increase our understanding. Finally, however, it will be interesting to determine how long the currently reported survey questionnaire findings of ulcerative colitis symptom severity improvement will continue.
APPENDIX: QUESTIONNAIRE USED TO OBTAIN INFORMATION FROM PATIENTS
CONCERNING ULCERATIVE COLITIS SYMPTOMS 10.
The year before transplant The time after transplant 11. On average, how many days per month were you unable to function completely normally in your daily activities because of ulcerative colitis or its complications during the year before your transplant and during the last 3 months? Use the code shown below. The year before transplant Now A = 1-2 days per month B = 3-4 days per month C = 4-6 days per month D = more than 6 but not every day E = nearly every day 12. Which description best describes your present activity? (Circle the correct answer) Thank you very much for completing the questionnaire. The space below is for you to give any additional information that you think would be helpful and for further explanation of any of your answers above.
